[PDF][PDF] Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive …
B Kaufman, JR Mackey, MR Clemens… - Journal of Clinical …, 2009 - researchgate.net
Journal of Clinical Oncology, 2009•researchgate.net
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal
Women With Human Epidermal Growth Fact Page 1 Trastuzumab Plus Anastrozole Versus
Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth
Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results
From the Randomized Phase III TAnDEM Study Bella Kaufman, John R. Mackey, Michael R.
Clemens, Poonamalle P. Bapsy, Ashok Vaid, Andrew Wardley, Sergei Tjulandin, Michaela …
Women With Human Epidermal Growth Fact Page 1 Trastuzumab Plus Anastrozole Versus
Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth
Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results
From the Randomized Phase III TAnDEM Study Bella Kaufman, John R. Mackey, Michael R.
Clemens, Poonamalle P. Bapsy, Ashok Vaid, Andrew Wardley, Sergei Tjulandin, Michaela …
Purpose
TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor–copositive metastatic breast cancer (MBC).
researchgate.net